News / Health

    Ebola Emergency Turns Spotlight on Experimental Drugs

    Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
    Tekmira Pharmaceuticals Corporation's head office is pictured in Burnaby, British Columbia Aug. 5, 2014.
    Reuters

    With hundreds of patients in Africa suffering the devastating effects of Ebola, health experts are scrambling to determine which drugs might offer the best experimental treatment, and researchers are being pressed by government officials to speed up their work.

    Three treatments have shown especially promising results in monkeys, the researchers said. One, produced by tiny California biotech Mapp Biopharmaceutical, gained international prominence this week when it was given to two U.S. aid workers who contracted Ebola in West Africa and have since shown signs of improvement.

    Others are from Vancouver-based Tekmira Pharmaceuticals and privately-held Profectus BioSciences, of Tarrytown, NY.

    Click to enlargeClick to enlarge
    x
    Click to enlarge
    Click to enlarge

    On Wednesday the World Health Organization said it would discuss next week the ethics of using Ebola drugs that have never been cleared for human use, wary of a long history of medicines being tested on people who were never properly informed of the risks. In the countries hardest hit by Ebola, suspicion of foreign medical workers is already widespread.

    But the health minister of Nigeria, Onyenbuchi Chukwu, told reporters this week that he had asked U.S. health officials about access to experimental Ebola therapies. U.S. drugmakers are fielding questions from government officials about their ability to supply treatments in sufficient quantities should the request come.

    "For years we've told the government you need to invest a little bit of money in this," said Profectus chief scientific officer John Eldridge. "And now it's, 'Oh my God, how fast can you make this?' "

    Officials at Mapp and Tekmira would not comment on efforts to make their treatments available in response to the outbreak.

    President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
    x
    President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.
    President Barack Obama speaks at a news conference at the conclusion of the U.S.-Africa Leaders Summit at the State Department in Washington, August 6, 2014.

    Speaking at a news conference on Wednesday, President Barack Obama said he lacks enough information to green-light Mapp's drug to treat the deadly Ebola virus and that the initial response should focus on public health measures to contain the outbreak.

    "We've got to let the science guide us, and I don't think all the information is in on whether this drug is helpful," the president said, adding that public health officials, in the course of containing the current outbreak, could assess whether new drugs or treatments can be effective.

    "We're focusing on the public health approach right now, but I will continue to seek information about what we're learning about these drugs going forward," he said.

    Dr. James Crowe, director of the Vaccine Center at Vanderbilt University who has been developing an Ebola treatment similar to Mapp's, said a Pentagon agency contacted him this week about his work and added he will meet next week with government scientists about accelerating his research.

    Monkey tests

    No Ebola drugs or vaccines have even entered mid-stage human trials, let alone been approved. The furthest along have been tested only in monkeys and a handful of humans.

    Mapp Biopharmaceutical began developing its ZMapp treatment more than a decade ago. It consists of a cocktail of nonoclonal antibodies, proteins that are highly specific for the Ebola virus and that are produced in bioengineered tobacco plants.

    In 2012 Mapp, working with scientists at the U.S. Army Military Research Institute of Infectious Diseases (USAMRIID) in Fort Detrick, Maryland, announced that when rhesus macaques received the cocktail an hour after infection by Ebola, all survived. When they received it 48 hours after infection, two-thirds survived.

    Last year, ZMapp passed a stiffer test: monkeys that had been infected with Ebola and developed fevers and other symptoms received the intravenous cocktail 104 to 120 hours after infection; 43 percent recovered.

    When the U.S. government decided to develop a contingency plan in case of accidental exposure to Ebola by one or two people at a U.S. research facility, it began storing a small amount of ZMapp, according to a source familiar with the contingency plan. ZMapp was chosen because the science is relatively easy to understand and the risks considered relatively small, the source said.

    The stock of Tekmira soared on expectations its Ebola drug might speed toward approval due to the crisis, or even be used in the current outbreak.

    Under a $140 million contract with the U.S. Department of Defense, it is developing a drug based on a genetic technology called RNA interference.

    The idea is to take strands of genetic material that are the virus's mirror image and, using nanoparticles, slip them into cells where Ebola is replicating. In theory, the RNA disables the virus.

    In experiments by scientists at the army research unit, Tekmira reported last November, most animals infected with lethal amounts of Ebola survived when given the RNA product. The survival rate was 83 percent when the animals were treated 24 or 48 hours after infection and 67 percent when they were treated 72 hours after.

    "It is amazing how well that works in non-human primates," said Ebola researcher Thomas Geisbert of the University of Texas Medical Branch, who has conducted several studies of the company's drug in monkeys.

    Human trials

    Last month, Tekmira announced that its early-stage human trial had been put on hold by the U.S. Food and Drug Administration, which had concerns about the drug's safety.

    Tekmira declined requests for an interview.

    Profectus BioSciences has also tested its Ebola vaccine in monkeys, with good results, said Eldridge.

    In a study with scientists at government biomedical research centers and the Pentagon, Profectus found that a single intramuscular injection protected all of the rhesus monkeys exposed to Ebola three weeks later. The company hopes to launch a human trial to assess the vaccine's safety within the next 12 months, Eldridge said.

    An experimental vaccine similar to Profectus's, developed by academic and government scientists, was rushed into emergency use only once. In 2009 a scientist in Germany working with Ebola-infected guinea pigs pricked her finger with a syringe containing the virus. The vaccine was flown from Canada, one of the sites where it was being developed.

    "She got that vaccine in less than 40 hours and survived," said Geisbert, though it's impossible to know whether that was because of the vaccine. "She lived. That's all I care about."

    With greater financial support, scientists said, Ebola treatments could be ready for use sooner. For less than $10 million, said Vanderbilt's Crowe, four or five of the experimental drugs could be ready for testing within in four months.

    All of them seem to be effective only in a small window after exposure, however.

    "Nothing on planet Earth is going to work if somebody comes in with full-blown Ebola hemorrhagic fever and they are 24 hours or 72 hours from death," said Geisbert. "The damage has been done."

    You May Like

    Video As Refugees Perish, Greek Graveyards Fill

    Before burial at overflowing cemeteries, unidentified dead being swapped for DNA, in case some day relatives come to learn their fate

    Russian Opposition Leader Sues Putin for Conflict of Interest

    Alexei Navalny tells VOA in exclusive interview why transfer of $2 billion from country’s wealth fund to company with ties to President Putin’s son-in-law triggered lawsuit

    Clinton, Sanders Fight for African American Votes

    Some African American lawmakers lining up to support Clinton in face of perceived surge by Sanders in race for Democratic nomination in presidential campaign

    This forum has been closed.
    Comment Sorting
    Comments
         
    by: John
    August 11, 2014 11:00 AM
    The US is still involved in the war in Somalia, decades after Bush Snr foolishly sent troops to help distribute food to the starving. The revolt by Boko Haram against polio vaccination goes from strength to strength. (Don't know whether the suit against the drug company that tested an experimental drug on the people of Kano has been settled though.) Yet some people still think we should give experimental drugs to Africans. They'll never learn!! The fact is, if Africans were really concerned about this disease, they'd have made a deal with Western drug companies to do the clinical trials of potential vaccines and cures decades ago. This doesn't take super technical skill; merely careful record keeping and a plentiful supply of victims---oops brave volunteers, to try the drugs. They just decided to wait until we panicked, so we'd provide all the money and guinea pigs ourselves. Must admit their strategy is working like a charm!!!

    Featured Videos

    Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
    As Refugees Perish, Greek Graveyards Filli
    X
    Hamada Elsaram
    February 11, 2016 8:01 PM
    Aid workers on the Greek island of Lesbos say they are struggling to bury the increasing number of bodies of refugees that have been recovered or washed up ashore in recent months.  The graveyards are all full, they say, yet as tens of thousands of people clamor to get out of Syria, it is clear refugees will still be coming in record numbers. For VOA, Hamada Elrasam reports from Lesbos, Greece.
    Video

    Video As Refugees Perish, Greek Graveyards Fill

    Aid workers on the Greek island of Lesbos say they are struggling to bury the increasing number of bodies of refugees that have been recovered or washed up ashore in recent months.  The graveyards are all full, they say, yet as tens of thousands of people clamor to get out of Syria, it is clear refugees will still be coming in record numbers. For VOA, Hamada Elrasam reports from Lesbos, Greece.
    Video

    Video To Fight Zika, Scientists Target Mosquitoes

    Mosquitoes strike again. The Zika virus outbreak is just the latest headline-grabbing epidemic carried by these biting pests, but researchers are fighting back with new ways to control them. VOA's Steve Baragona takes a look.
    Video

    Video Mosul Refugees Talk About Life Under IS

    A top U.S. intelligence official told Congress this week that a planned Iraqi-led operation to re-take the city of Mosul from Islamic State militants is unlikely to take place this year. IS took over the city in June 2014, and for the past year and a half, Mosul residents have been held captive under its rule. VOA's Zana Omar talked to some families who managed to escape. Bronwyn Benito narrates his report.
    Video

    Video Scientists Make Progress Toward Better Diabetes Treatment, Cure

    Scientists at two of the top U.S. universities say they have made significant advances in their quest to find a more efficient treatment for diabetes and eventually a cure. According to the International Diabetes Federation, the disease affects more than 370 million people worldwide. VOA’s George Putic reports.
    Video

    Video NATO to Target Migrant Smugglers

    NATO has announced plans to send warships to the Aegean Sea to target migrant smugglers in the alliance's most direct intervention so far since a wave of people began trying to reach European shores.
    Video

    Video Russia's Catholics, Orthodox Hopeful on Historic Pope-Patriarch Meeting

    Russia's Catholic minority has welcomed an historic first meeting Friday in Cuba between the Pope and the Patriarch of Russia's dominant Orthodox Church. The Orthodox Church split with Rome in 1054 and analysts say politics, both church and state, have been driving the relationship in the centuries since. VOA's Daniel Schearf reports from Moscow.
    Video

    Video Used Books Get a New Life on the Streets of Lagos

    Used booksellers are importing books from abroad and selling them on the streets of Africa's largest city. What‘s popular with readers may surprise you. Chris Stein reports from Lagos.
    Video

    Video After NH Primaries All Eyes on South Carolina

    After Tuesday's primary in New Hampshire, US presidential candidates swiftly turned to the next election coming up in South Carolina. The so-called “first-in-the-South” poll may help further narrow down the field of candidates. Zlatica Hoke reports.
    Video

    Video US Co-ed Selective Service Plan Stirs Controversy

    Young women may soon be required to register with the U.S. Selective Service System, the U.S. government agency charged with implementing a draft in a national emergency. Top Army and Marine Corps commanders told the Senate Armed Services Committee recently that women should register, and a bill has been introduced in Congress requiring eligible women to sign up for the military draft. The issue is stirring some controversy, as VOA’s Bernard Shusman reports from New York.
    Video

    Video Lessons Learned From Ebola Might Help Fight Zika

    Now that the Ebola epidemic has ended in West Africa, Zika has the world's focus. And, as Carol Pearson reports, health experts and governments are applying some of the lessons learned during the Ebola crisis in Africa to fight the Zika virus in Latin America and the Caribbean.
    Video

    Video Smartphone Helps Grow Vegetables

    One day, you may be using your smartphone to grow your vegetables. A Taipei-based company has developed a farm cube — a small, enclosed ecosystem designed to grow plants indoors. The environment inside is automatically adjusted by the cube, but it can also be controlled through an app. VOA's Deborah Block has more on the gardening system.
    Video

    Video Illinois Voters Have Mixed Emotions on Obama’s Return to Springfield

    On the ninth anniversary of the launch of his quest for national office, President Barack Obama returned to Springfield, Illinois, to speak to the Illinois General Assembly, where he once served as state senator. His visit was met with mixed emotions by those with a front-row seat on his journey to the White House. VOA's Kane Farabaugh reports.
    Video

    Video Exhibit Turns da Vinci’s Drawings Into Real Objects

    In addition to being a successful artist, Renaissance genius Leonardo da Vinci designed many practical machines, some of which are still in use today, although in different forms. But a number of his projects were never realized — until today. VOA’s George Putic reports.
    Video

    Video Heated Immigration Debate Limits Britain’s Refugee Response

    Compared to many other European states, Britain has agreed to accept a relatively small number of Syrian refugees. Just over a thousand have arrived so far -- and some are being resettled in remote corners of the country. Henry Ridgwell reports on why Britain’s response has lagged behind its neighbors.
    Video

    Video Russia's Car Sales Shrink Overall, But Luxury and Economy Models See Growth

    Car sales in Russia dropped by more than a third in 2015 because of the country's economic woes. But, at the extreme ends of the car market, luxury vehicles and some economy brands are actually experiencing growth. VOA's Daniel Schearf reports from Moscow.